Onco-Innovations Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced the successful completion of a pilot project with Kuano Ltd. that leverages artificial intelligence and quantum computing to advance the company’s PNKP Inhibitor Technology (ONC010). This milestone marks a significant step in the computational analysis of the inhibitor, potentially streamlining the path toward preclinical development.

The collaboration with Kuano Ltd. utilized AI-enabled and quantum-based computational analysis to better understand how Onco’s PNKP inhibitor and related analogs interact with their target. Kuano delivered molecular modeling and computational findings that strengthened Onco’s understanding, producing a refined structural hypothesis for PNKP inhibition. This framework is expected to support structure-based optimization and future evaluation of the compound.

According to the company, the project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. These results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping, and AI-assisted generative compound design. The goal is to improve compound prioritization and accelerate progress toward preclinical development.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. The successful completion of this pilot project underscores Onco’s commitment to innovative solutions in cancer treatment.

For more details, view the full press release at https://ibn.fm/SdQqD. For the latest news and updates relating to ONNVF, visit the company’s newsroom at https://ibn.fm/ONNVF.